Cepton Introduces the World’s Smallest Wide Field of View Lidar Sensor for Near-Range Applications
Cepton Technologies, Inc., a leading provider of state-of-the-art, intelligent, lidar-based solutions, has announced its path-breaking miniature lidar sensor – the Nova - priced at less than $100 for high volume automotive applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210112005035/en/
With a lidar target size of 3.5 cm (W) x 3.5 cm (H) x 7.5 cm (D), and weighing less than 350 g, the Nova is extremely compact and easily embeddable for automotive applications. © 2021 Cepton Technologies.
The Nova is a wide angle near-range lidar sensor intended to address major gaps in proximity detection of objects with current sensor technologies. Featuring best-in-class, high resolution 3D imaging with a high field of view (FOV) of 90-120° (H) and 60-90° (V), depending on configuration, Nova sets a worldwide benchmark with its unprecedented combination of compactness, FOV coverage and affordability.
Powered by Cepton’s patented and proven Micro Motion Technology (MMT®), the non-rotational, mirrorless, and frictionless Nova lidar can be hidden all around a vehicle to provide a complete 360° view of its immediate surroundings. With a lidar target size of 3.5 cm (W) x 3.5 cm (H) x 7.5 cm (D), and weighing less than 350 g, the ultra-small Nova is an easily embeddable lidar sensor that not only enables optimal styling choices but demonstrates the scalability of MMT® to the smallest form factors.
Nova has an angular resolution of up to 0.3°, with a maximum range of up to 30 m and is therefore ideal for automotive Advanced Driver Assistance Systems (ADAS) and autonomous vehicle (AV) applications such as blind spot detection, small object detection, automated park assist and free space estimation around the vehicle. For vehicles, a multi-lidar architecture can be facilitated, thereby creating a virtual safety zone all around while minimizing disruption to vehicle design aesthetics.
Nova is ideally suited for accurate detection of objects in proximity, such as small children, on-road objects, road edges, stationary objects and more. With this level of capability and its ultra-compact design, Nova can not only support ADAS and AV applications but also autonomous ground vehicle (AGV) and smart industrial applications.
With lidar’s increasing presence in cars and trucks, Cepton has been innovating its technology to meet the stringent requirements from OEMs and Tier 1s while striving to advance lidar designs that enable easy integration in the next generation of automobiles. Nova is the latest representation of Cepton’s state-of-the-art lidar innovation, that encompasses the goal of automotive-grade reliability, low power (<3.5 W) and high performance, along with an elegant, minimalistic design that requires only small amounts of real estate in the vehicle body.
Nova’s modular design and easily accessible components make it highly manufacturable, with very low cost at high volume. Previously, Cepton was one of the first in the industry to announce a <$1,000 volume lidar price for high performance, long range lidar (Vista-X90). Consistent with that trend, Nova is the first high field of view, near-range lidar with a <$100 price point for high automotive volumes. This fulfils Cepton’s objective to bring to market scalable, mass-market lidar solutions that enable the automotive industry to substantially accelerate safety and autonomy innovations in the next generation of vehicles.
“The Nova is an industry-first, transformational lidar that fundamentally changes the game for near-field sensing,” said Cepton CEO Dr. Jun Pei. “Currently, consumer vehicles have been limited to technologies that cannot facilitate true Level 3 or Level 4 autonomy for the mass market. Radars, cameras and ultrasonic sensors suffer from high false positives and false negatives. Rotational lidars are not embeddable, making them impractical for consumer vehicles. Near-range flash lidars either lack the wide field of view or cannot match the power and size requirements to be discretely hidden all around the vehicle. The Nova represents path-breaking lidar innovation for the automotive industry in that it achieves a level of performance that is unmatched for such a small form factor.”
Nova is targeted for high volume production starting in 2023. Due to anticipated high demand for samples, Nova will only be available to select customers in 2021 through Cepton’s Early Access Program. If you would like to be part of this program or would like more details, please contact Mitch Hourtienne, Cepton Senior Director of Business Development at mitch.hourtienne@cepton.com.
To learn more about the Nova and Cepton’s automotive grade lidar capabilities, join Cepton at the upcoming digital CES 2021, from January 11th to 14th, via our virtual booth page (CES registration required). On Jan 12th, Cepton CMO, Dr. T. R. Ramachandran will join North American Lighting (NAL) for a virtual panel discussion on “Impact of Sensors on Mobility” at 11 a.m. (PST) and present at an online NAL-hosted webinar “Lidar, What’s the Future?” at 2 p.m. (PST). Watch the online sessions for free to learn more about how lidar is transforming the world and how Cepton’s smart lidar solutions are ideally suited for automotive and smart infrastructure applications.
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. Cepton’s patented MMT®-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, Japan and India, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005035/en/
Contact information
Faithy Li, Cepton Technologies, media@cepton.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
